Table 2:  Results of met analysis.

Cancer type

Fixed effect model Overall Ratio 

All cancer sites morbidity children and adults together

*1.07

(90% CI 1.04, 1.10

(95% CI 1.03, 1.11)

(99% CI 1.02, 1.12)

All cancer sites morbidity adults

*1.11

(90% CI 1.06, 1.15)

(95% CI 1.06, 1.16)

(99% CI 1.04, 1.18)

All cancer sites mortality children and adults

0.92

(90% CI 0.89, 0.96)

(95% CI 0.88, 0.97)

(99% CI 0.87, 0.98)

All cancer sites mortality adults

0.92

(90%CI 0.88, 0.96)

(95%CI 0.88, 0.97)

(99%CI 0.86, 0.98)

Lymphoma  morbidity

*1.55

(90% CI 1.27, 1.90)

(95% CI 1.22, 1.97)

(99% CI 1.14, 2.12)

Lymphoma and multiple myeloma mortality

1.17

(90% CI 0.99, 1.38)

(95% CI 0.96, 1.42)

(99% CI 0.91, 1.51) 

Childhood leukemia morbidity

*1.35

(90% CI 1.20, 1.53)

(95% CI 1.17, 1.56)

(99% CI 1.12, 1.64)

All leukemia morbidity adults

*1.24

(90%CI 1.14, 1.35)

(95%CI 1.12, 1.37)

(99%CI 1.09, 1.42)

All leukemia mortality adults

 

*1.29

(90% CI 1.16, 1.44)

(95% CI 1.13, 1.47)

(99% CI 1.09, 1.53)

 

Melanoma morbidity

*1.47

(90% CI 1.27, 1.69)

(95% CI 1.24, 1.74)

99%) CI 1.18, 1.83)

Breast cancer morbidity

*1.23

(90% CI 1.12, 1.36)

(95% CI 1.10, 1.39)

(99% CI 1.06, 1.44)

Brain (and CNS) cancer morbidity

*1.44

(90% CI 1.22, 1.69)

(95% CI 1.18, 1.74)

(99% CI 1.11, 1.85)

Brain  (and CNS) cancer mortality

1.18

(90% CI 0.97, 1.43)

(95% CI 0.94, 1.48)

(99% CI 0.87, 1.59)

Brain cancer morbidity in children

1.11

(90% CI 0.97, 1.28)

(95% CI 0.94, 1.32)

(99% CI 0.90, 1.39)

Testicular cancer morbidity

1.24

(90% CI 1.03, 1.50) **

(95% CI 0.99, 1.56)

(99%CI 0.92, 1.67)

 

* Statistically significant

** Borderline significant